Taken together, these in vivo studies demonstrated that the combination of ICIs (a-PDL1 and a-CTLA4) with LDHIs (Oxa and NHI-2) enhances the efficacy of ICIs in a melanoma tumor model. Here, CD274 is linked to melanoma.